Scisparc Ltd（SPRC）股票分析SPRCScisparc Ltd

Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, SciSparc Ltd (SPRC) is not a strong buy due to its recent performance and financial metrics. The stock is trading at $4.47, which is significantly down 64.52% year-to-date and 85.69% over the past year. The RSI is at 42.375, indicating it is nearing oversold territory, but it has not yet reached a buying signal. Additionally, the forward P/E ratio is at 0, reflecting uncertainty in future earnings. While there was a notable 70.54% increase in stock price recently due to advancements in its technology, the overall trend remains negative, and the stock has a high risk of further decline given its current financial instability and negative margins. The main risk is highlighted by the net margin of -2041.65% in Q2 2025, indicating severe losses.